Epidemiological, pathological, and molecular characteristics of lung cancer in Casablanca, Morocco: a retrospective study

摩洛哥卡萨布兰卡肺癌的流行病学、病理学和分子特征:一项回顾性研究

阅读:1

Abstract

INTRODUCTION: lung cancer remains a significant global health concern, responsible for the highest number of cancer-related deaths worldwide. In Morocco, it is the most prevalent cancer among men. This study aimed to describe the epidemiological characteristics of lung cancer and to explore the molecular profile of lung adenocarcinoma cases. METHODS: a retrospective analysis was carried out over a 24-month period, from January 2020 to December 2021, at the Pathology Department of Ibn Rochd University Hospital in Casablanca, Morocco, encompassing 1,426 lung cancer cases. Statistical analyses were performed using GraphPad Prism 8 software. RESULTS: our study reveals that the mean age was 59.9±12.06 years (median: 61 years, IQR: 54-67). A clear male predominance was observed in 75.9% (n=1,083). The most common histological type was adenocarcinoma, representing 49.6% (n=708). In adenocarcinoma cases, thyroid transcription factor-1 (TTF-1) expression was positive in 95.5% (n=469). Programmed death-ligand 1 (PD-L1) was mostly negative, with a tumor proportion score (TPS) <1% in 59.7% (n=83), 1-49% in 13.7% (n=19), and ≥50% in 26.6% (n=37). Anaplastic lymphoma kinase (ALK) expression was positive in only 4.1% (n=3) of cases. Epidermal growth factor receptor (EGFR) mutations were found in 22.2% (n=24), predominantly Ex19Del in 66.6% (n=16). All ALK-positive cases were PD-L1 negative (100%, n=3), while PD-L1 expression (TPS≥1%) was detected in 38.9% (n=7) of EGFR-mutated adenocarcinomas. CONCLUSION: this study characterizes lung adenocarcinoma as the predominant histological type, elucidates its principal molecular features and enables the determination of possible correlations between EGFR status, PD-L1 and ALK expression among Moroccan patients.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。